SGK1 and Parkinson disease: We further assessed the therapeutic potential of the SGK1 inhibitor in another PD mouse model generated by injecting human SNCA PFF into the SN of the midbrain, in combination with adeno‐associated virus (AAV)‐mediated overexpression of human SNCA (Fig 7K), which is regarded as an animal model that is relevant to PD pathogenesis and disease progress (Thakur et al, 2017).